Alpha memo: resveratrol exercise context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• The memo could briefly note that the two receipts differ in exercise modality as a candidate moderator, beyond dose/duration/health status.
• Receipt 1 framing could more explicitly cite the published year/author handling to track the pilot trial as 'feasibility/safety' rather than efficacy-confirming.

Reviewer note

Triage: elite-tier accept. The memo delivers one bounded, source-grounded signal — resveratrol's interaction with exercise training differs by population and endpoint rather than uniformly helping — supported by two well-matched primary RCTs. The title (resveratrol exercise context boundary) aligns with both receipts, and the central claim is appropriately qualified as a qualitative sign-of-effect difference, not a magnitude claim. Limitations are specific and material: both trials are small (N=60, n=27), doses differ (250 vs 500/1000 mg), durations differ (8 vs 12 wk), and populations differ (healthy inactive aged men vs older adults with functional limitations), making the moderator unisolable. The proposed falsifier (an RCT in older adults with functional limitations using Receipt 1's dose/duration while measuring Receipt 2's cardiovascular endpoints) is concrete and actionable. Source_grounding is high: both citations have populated excerpts that confirm the key claims (feasibility framing for Receipt 1; attenuation of training-induced cardiovascular gains for Receipt 2). Synthesis is coherent though compressed, integrating the two receipts into a single directional contrast with explicit falsifiability criteria. No clinical, policy, or broad-consensus claims are made. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis